Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype

Journal of Clinical Investigation

Volumn 100, Issue 10, 1997, Pages 2611-2621

  Rybalkin, Sergei D ^a   Bornfeldt, Karin E ^b   Sonnenburg, William K ^a   Rybalkina, Irina G ^a   Kwak, Keith S ^a   Hanson, Kim ^b   Krebs, Edwin G ^a   Beavo, Joseph A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Angioplasty; Atherosclerosis; Ion exchange chromatography; RNA probes; Western blotting

Indexed keywords

CALMODULIN; CYCLIC AMP; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE;

ADULT; ANGIOPLASTY; ANIMAL CELL; ARTICLE; ATHEROSCLEROSIS; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INDUCTION; HUMAN; HUMAN CELL; ION EXCHANGE CHROMATOGRAPHY; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RESTENOSIS; SMOOTH MUSCLE FIBER;

EID: 0030831875     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119805     Document Type: Article

References (42)

1. Ross, R. 1993. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 362:801-809.
2. Thyberg, J., U. Hedin, M. Sjölund, L. Palmberg, and B.A. Bottger. 1990. Regulation of differentiated properties and proliferation of arterial smooth muscle cells. Arteriosclerosis. 10:966-990.
3. Lindgren, S., A. Rascon, K.E. Andersson, V. Manganiello, and E. Degerman. 1991. Selective inhibition of cGMP-inhibited and cGMP-noninhibited cyclic nucleotide phosphodiesterases and relaxation of rat aorta. Biochem. Pharmacol. 42:545-552.
4. McDaniel, N.L., C.M. Rembold, and R.A. Murphy. 1994. Cyclic nucleotide dependent relaxation in vascular smooth muscle. Can. J. Physiol. Pharmacol. 72:1380-1385.
5. Bornfeldt, K.E. 1996. Intracellular signaling in arterial smooth muscle migration versus proliferation. Trends Cardiovasc. Med. 6:143-151.
6. Cook, S.J., and F. McCormick. 1993. Inhibition by cAMP of Ras-dependent activation of Raf. Science. 262:1069-1072.
7. Graves, L.M., K.E. Bornfeldt, E.W. Raines, B.C. Potts, S.G. Macdonald, R. Ross, and E.G. Krebs. 1993. Protein kinase A antagonizes platelet-derived growth factor-induced signaling by mitogen-activated protein kinase in human arterial smooth muscle cells. Proc. Natl. Acad. Sci. USA. 90:10300-10304.
8. Wu, J., P. Dent, T. Jelinek, A. Wolfman, M.J. Weber, and T.W. Sturgill. 1993. Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3′,5′-monophosphate. Science. 262:1065-1069.
9. Graves, L.M., K.E. Bornfeldt, G.M. Argast, E.G. Krebs, X. Kong, T.A. Lin, and J.C. Lawrence, Jr. 1995. cAMP-and rapamycin-sensitive regulation of the association of eukaryotic initiation factor 4E and the translational regulator PHAS-I in aortic smooth muscle cells. Proc. Natl. Acad. Sci. USA. 92:7222-7226.
10. Monfar, M., K.P. Lemon, T.C. Grammer, L. Cheatham, J. Chung, C.J. Vlahos, and J. Blenis. 1995. Activation of pp70/85 S6 kinases in interleukin-2-responsive lymphoid cells is mediated by phosphatidylinositol 3-kinase and inhibited by cyclic AMP. Mol. Cell. Biol. 15:326-337.
11. Kato, J.Y., M. Matsuoka, K. Polyak, J. Massague, and C.J. Sherr. 1994. Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell. 79:487-496.
12. 2+ mobilization, by cyclic AMP and GMP in rabbit aortic smooth-muscle cells. Biochem. J. 268:527-532.
13. Iyengar, R. 1996. Gating by cyclic AMP: expanded role for an old signaling pathway. Science. 271:461-463.
14. Beavo, J.A. 1995. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. 75:725-748.
15. Rybalkin, S.D., and J.A. Beavo. 1996. Multiplicity within cyclic nucleotide phosphodiesterases. Biochem. Soc. Trans. 24:1005-1009.
16. Ahn, H.S., W. Crim, B. Pitts, and E.J. Sybertz. 1992. Calcium-calmodulin-stimulated and cyclic-GMP-specific phosphodiesterases. Tissue distribution, drug sensitivity, and regulation of cyclic GMP levels. Adv. Second Messenger Phosphoprotein Res. 25:271-288.
17. Saeki, T., and I. Saito. 1993. Isolation of cyclic nucleotide phosphodiesterase isozymes from pig aorta. Biochem. Pharmacol. 46:833-839.
18. Lugnier, C., P. Schoeffter, B.A. Le, E. Strouthou, and J.C. Stoclet. 1986. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem. Pharmacol. 35:1743-1751.
19. Miyahara, M., M. Ito, H. Itoh, T. Shiraishi, N. Isaka, T. Konishi, and T. Nakano. 1995. Isoenzymes of cyclic nucleotide phosphodiesterase in the human aorta: characterization and the effects of E4021. Eur. J. Pharmacol. 284:25-33.
20. Eckly, A.E., and C. Lugnier. 1994. Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway. Br J. Pharmacol. 113:445-450.
21. Vroom, M.B., M. Pfaffendorf, H.B. van Wezel, and P.A. van Zwieten. 1996. Effect of phosphodiesterase inhibitors on human arteries in vitro. Br. J. Anaesth. 76:122-129.
22. Kauffman, R.F., K.W. Schenck, B.G. Utterback, V.G. Crowe, and M.L. Cohen. 1987. In vitro vascular relaxation by new inotropic agents: relationship to phosphodiesterase inhibition and cyclic nucleotides. J. Pharmacol. Exp. Ther. 242:864-872.
23. Pan, X.L., E. Arauz, J.J. Krzanowski, D.F. Fitzpatrick, and J.B. Polson. 1994. Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells. Biochem. Pharmacol. 48:827-835.
24. Souness, J.E., G.A. Hassall, and D.P. Parrott. 1992. Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors. Biochem. Pharmacol. 44:857-866.
25. Ross, R., and B. Kariya. 1980. Morphogenesis of vascular smooth muscle in atherosclerosis and cell culture. In Handbook of Physiology. Section 2: The Cardiovascular System. D.F. Bohr, A.P. Somlyo, H.V. Sparks, and S.R. Geiger, editors. American Physiological Society, Bethesda, MD. 69-91.
26. Beltman, J., D.E. Becker, E. Butt, G.S. Jensen, S.D. Rybalkin, B. Jastorff, and J.A. Beavo. 1995. Characterization of cyclic nucleotide phosphodiesterases with cyclic GMP analogs: topology of the catalytic domains. Mol. Pharmacol. 47:330-339.
27. Hansen, R.S., H. Charbonneau, and J.A. Beavo. 1988. Purification of calmodulin-stimulated cyclic nucleotide phosphodiesterase by monoclonal antibody affinity chromatography. Methods Enzymol. 159:543-557.
28. Bradford, M.M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254.
29. Ausubel, F.M., R. Brent, R.E. Kingston, D.D. Moore, J.G. Seidman, J.A. Smith, and K. Struhl. 1994. Current Protocols in Molecular Biology. John Wiley & Sons, Inc., New York.
30. Sonnenburg, W.K., D. Seger, and J.A. Beavo. 1993. Molecular cloning of a cDNA encoding the "61 kDa" calmodulin-stimulated cyclic nucleotide phosphodiesterase. Tissue-specific expression of structurally related isoforms. J. Biol. Chem. 268:645-652.
31. Sonnenburg, W.K., D. Seger, K.S. Kwak, J. Huang, H. Charbonneau, and J.A. Beavo. 1995. Identification of inhibitory and calmodulin-binding domains of the PDE1A1 and PDE1A2 calmodulin-stimulated cyclic nucleotide phosphodiesterases. J. Biol. Chem. 270:30989-31000.
32. McCombie, W.R., C. Heiner, J.M. Kelley, M.G. Fitzgerald, and J.D. Gocayne. 1992. Rapid and reliable fluorescent cycle sequencing of double-stranded templates. DNA Seq. 2:289-296.
33. Genetic Computer Group. 1991. Program Manual for the GCG Package. Genetic Computer Group, Madison, WI.
34. Yan, C., A.Z. Zhao, J.K. Bentley, and J.A. Beavo. 1996. The calmodulin-dependent phosphodiesterase gene PDE1C encodes several functionally different splice variants in a tissue-specific manner. J. Biol. Chem. 271:25699-25706.
35. Harlow, E., and D. Lane. 1988. Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
36. Yan, C., A.Z. Zhao, J.K. Bentley, K. Loughney, K. Ferguson, and J.A. Beavo. 1995. Molecular cloning and characterization of a calmodulin-dependent phosphodiesterase enriched in olfactory sensory neurons. Proc. Natl. Acad. Sci. USA. 92:9677-9681.
37. Loughney, K., T.J. Martins, E.A. Harris, K. Sadhu, J.B. Hicks, W.K. Sonnenburg, J.A. Beavo, and K. Ferguson. 1996. Isolation and characterization of cDNAs corresponding to two human calcium, calmodulin-regulated, 3′,5′ cyclic nucleotide phosphodiesterases. J. Biol. Chem. 271:796-806.
38. Bentley, J.K., A. Kadlecek, C.H. Sherbert, D. Seger, W.K. Sonnenburg, H. Charbonneau, J.P. Novack, and J.A. Beavo. 1992. Molecular cloning of cDNA encoding a "63"-kDa calmodulin-stimulated phosphodiesterase from bovine brain. J. Biol. Chem. 267:18676-18682.
39. Hurwitz, R.L., K.M. Hirsch, D.J. Clark, V.N. Holcombe, and M.Y. Hurwitz. 1990. Induction of a calcium/calmodulin-dependent phosphodiesterase during phytohemagglutinin-stimulated lymphocyte mitogenesis. J. Biol. Chem. 265:8901-8907.
40. Knudtson, M.L., V.F. Flintoft, D.L. Roth, J.L. Hansen, and H.J. Duff. 1990. Effect of short-term prostacyclin administration on restenosis after percutaneous transluminal coronary angioplasly. J. Am. Coll. Cardiol. 15:691-697.
41. Gershlick, A.H., D. Spriggins, S.W. Davies, C.Y.D. Syndercombe, J. Timmins, A.D. Timmis, M.T. Rothman, C. Layton, and R. Balcon. 1994. Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial. Br. Heart J. 71:7-15.
42. Vane, J.R., and R.M. Botting. 1995. Pharmacodynamic profile of prostacyclin. Am. J. Cardiol. 75:3A-10A.